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Prevalence of Surgical Procedures at Symptomatic Onset of Prion Disease
Amanda L. Porter, MD; Christian C. Prusinski, DO; Evelyn Lazar, MD; Clara Yuh, DO; Robert C. Bucelli, MD, PhD; Brian S. Appleby, MD; Gregory S. Day, MD, MSc, MSCI

Introduction

+ Invited Commentary

Creutzfeldt-Jakob disease (CJD) is a rapidly progressive fatal prion disease. Although most cases are
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sporadic or inherited, prions may be transmitted via contaminated tissues or durable medical
equipment.1,2 The risk of iatrogenic transmission is highest following procedures involving the central
nervous system, where prion burden is highest.2,3 However, experimental models suggest that
transmission may occur following contact with other tissues (eg, nasal mucosa, lung, lymph nodes,
and spleen).4 If these models are accurate, surgical procedures involving these tissues may pose a
risk to future patients. To evaluate the potential scope of this problem, we determined the frequency
of invasive procedures performed in patients with CJD at multiple tertiary care centers.

Methods
Protocols for this case-control study were approved by the Mayo Clinic institutional review board. A
waiver of consent was granted for the use of retrospective, deidentified data. This study follows the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline. An automated search of Mayo Clinic records identified 252 of 1 843 675 patients with
diagnostic evaluation including “CJD” or “prion disease” evaluated from January 2014 (the time at
which specific biomarkers of prion disease were incorporated within clinical practice) to February
2021 at Mayo Clinic locations in Rochester, Minnesota; Jacksonville, Florida; and Phoenix, Arizona.
Fourteen patients at Washington University (Saint Louis, Missouri) were enrolled from February
2016 to December 2019 within prospective studies of rapid progressive dementia. Available records
were dual-reviewed (April 2021) to identify patients who met criteria for probable CJD
(neuropsychiatric disorder with positive cerebrospinal fluid real-time quaking-induced recovery
assays; or rapidly progressive dementia with 1 or more of the following signs and symptoms:
myoclonus, visual or cerebellar signs, pyramidal or extrapyramidal signs, akinetic mutism, and
consistent brain magnetic resonance imaging; 71 patients) or definite CJD (pathologically or
genetically confirmed, 50 patients)5 and to capture surgical procedures. Procedures performed
within 1 year of the onset of symptoms attributed to CJD were counted to include the
presymptomatic period associated with latent prion accumulation. Procedures were stratified by
risk of prion contamination of instruments.3,4 Statistical analysis was performed using SPSS
statistical software version 28.0 (IBM), using Pearson χ2 tests for categorical variables and
Mann-Whitney U tests for continuous variables to evaluate the association between patient-specific
factors and procedures. Significance was set at P < .10 due to the exploratory nature of this analysis.
Data were analyzed from March 2021 to June 2021.

Results
In total, 26 of 121 patients (21%) (63 female patients [52%]; median [range] age, 65.4 [21.9 to 81.5]
years) with CJD underwent 55 procedures, including high-risk procedures in 2 patients with
neuropathologically proven CJD (Table 1). Procedures were more frequent in patients with a history
of arthritis (odds ratio [CI] 5.58 [1.16-26.7], P = .02) and possibly less frequent in patients with
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behavioral symptoms or signs at presentation (odds ratio [CI] 0.43 [0.16-1.17]. P = .093) (Table 2).
Median times from symptom onset to brain magnetic resonance imaging and electroencephalogram
were greater in patients who underwent procedures, suggesting that diagnostic delays were
associated with procedures. Seventeen of 32 procedures (53%) were performed in the months prior
to symptomatic onset (median [range,] −5.4 [−0.2 to −10.8] months). Appropriate procedural
precautions were observed in 1 patient.

Discussion
Invasive procedures were frequently performed in patients with CJD included in this case-control
study. Actual numbers of procedures may have been even greater, recognizing that procedures
performed at outside hospitals may have been overlooked or excluded from records. Replication of
study methods within additional hospitals—including community-based centers—is required to
confirm these findings and establish the generalizability of results.
Features of sporadic CJD typically manifest in the sixth through eighth decades of life (median
age, 68 years),5 a time when gait abnormalities, sensorimotor complaints and visual changes may be

Table 1. Surgical Procedures Performed in Patients With Creutzfeldt-Jakob Disease Using Durable Instruments,
Stratified by Risk of Contamination of Instruments With Prionsa

Indication

Procedures,
No. (%)
(N = 55)

Ophthalmic artery aneurysm clipping

Unruptured aneurysm

1 (50)

Brain biopsy

Diagnostic

Procedures
High risk

2 (4)

Moderate risk

1 (50)
12 (22)

Joint replacement (knee or hip)

Fracture, osteoarthritis

4 (33)

Arthroscopy

Osteoarthritis

1 (8)

Bilateral carpal tunnel release

Carpal tunnel syndrome

1 (8)

Cholecystectomy (laparoscopic)

Cholelithiasis

1 (8)

Hernia repair and gastroplasty (laparoscopic)

Dysphagia

1 (8)

Laminectomy and facetectomy

Spinal stenosis

1 (8)

Laparoscopic salpingo-oophorectomy

Ovarian mass

1 (8)

Open-reduction internal fixation

Tibia or fibula fracture

1 (8)

Rotator cuff repair (laparoscopic)

Rotator cuff tear

1 (8)

Low risk

18 (33)

Endoscopy, gastrointestinal

Screening with or without polypectomy

9 (50)

Oral and maxillofacial surgery

Dental grafting

4 (22)

Nasal, laryngoscopy

Dysarthria, laryngitis

2 (11)

Bronchoscopy

Pneumonia

1 (6)

Cystoscopy

Retention

1 (6)

Ophthalmic surgery

Cataract removal

Negligible risk

1 (6)
23 (42)

Biopsy, skin or lip

Diagnostic or therapeutic

5 (22)

Joint injection or aspiration

Diagnostic or therapeutic

5 (22)

Angiography with or without stenting

Diagnostic or therapeutic

3 (13)

Central venous catheter placement

Therapeutic

2 (9)

Endotracheal intubation

Therapeutic

2 (9)

Acupuncture

Therapeutic

1 (4)

Implantable loop recorder placement

Diagnostic

1 (4)

Epidural blood patch

Therapeutic

1 (4)

Occipital nerve block

Therapeutic

1 (4)

Ophthalmic surgery (laser photocoagulation)

Therapeutic

1 (4)

Subcutaneous fat aspirate

Diagnostic

1 (4)
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Procedures involving direct contact with central
nervous system tissues were deemed high risk.
Invasive procedures with disruption of mucosal or
lymphoid tissues (eg, joint replacement and intraabdominal laparotomy) were considered moderate
risk. Procedures with minimal disruption of mucosal
or lymphoid tissues (eg, endoscopy and
colonoscopy) were considered low risk. Invasive
procedures with disposable instruments only
involving contact with blood were deemed no or
negligible risk.3,4
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mistaken for common age-related surgically responsive conditions, leading to surgical procedures in
this cohort and others.6 Thus, it is essential to accurately decipher the cause of symptoms and signs
in clinical practice (eg, distinguishing between difficulty walking due to joint pain vs ataxia due to
CJD). Preoperative risk assessment tools may identify patients at risk of CJD, for whom elective
surgical procedures should be deferred and emergent procedures completed under precautions.2
However, prescreening cannot prevent invasive procedures in presymptomatic patients. National
registries may address this problem. In the US, The National Prion Disease Pathology and Surveillance
Center systematically collects data from patients with suspected CJD. Incorporating questions on
recent invasive procedures would allow early notification of surgeons or facilities when a diagnosis of
CJD is confirmed, permitting quarantine, decontamination, or decommissioning of affected
instruments. This would also allow for prospective surveillance in larger numbers of patients,

Table 2. Demographic Characteristics, Symptoms and Signs at Presentation, and Results of Investigations
for Patients With Probable or Definite CJD
Patients, No. (%)

Characteristic

Total
(N = 121)

Underwent
procedure
(n = 26)

Did not undergo
procedure
(n = 95)

P value

Age at symptom onset, median (range), y

65.4 (21.9-81.5)

65.4 (21.9-78.9)

65.4 (32.3-81.5)

.58

Female

63 (52)

16 (62)

47 (49)

Male

58 (48)

10 (38)

48 (51)

Black

2 (2)

1 (4)

1 (1)

.32

White, nonHispanic

111 (92)

23 (88)

88 (93)

.49

Othera

8 (7)

2 (8)

6 (6)

.80

Vascular risk factors

75 (62)

19 (73)

56 (59)

.19

Cataracts

7 (6)

2 (8)

5 (5)

.64

Peripheral neuropathy

1 (1)

0

1 (1)

.60

Arthritis

7 (6)

4 (15)

3 (3)

.02

Cognitive

105 (87)

20 (77)

83 (87)

.18

Behavioral

45 (37)

6 (23)

39 (41)

.09

Vision loss or change

26 (21)

5 (19)

20 (21)

.84

Sensorimotor

97 (80)

20 (77)

65 (67)

.40

Ataxia

82 (68)

17 (65)

75 (79)

.15

Constitutional

15 (12)

3 (12)

12 (13)

.88

Time from symptom onset to presentation,
median (range), mo

1.9 (0-29.0)

2.6 (0.4-29.0)

1.7 (0-20.0)

.06

108/120 (90)

21/26 (81)

73/94 (78)

.73

2.8 (0-36.7)

5.9 (0-36.7)

2.7 (0-30.3)

.05

94/111 (85)

22/25 (88)

73/86 (85)

.70

Abbreviations: CJD, Creutzfeldt-Jakob disease; CSF,
cerebrospinal fluid; EEG, electroencephalogram; MRI,
magnetic resonance imaging.

3.3 (0.3-34.6)

5.0 (0.8-34.6)

3.2 (0.3-23.1)

.07

a

Other includes Asian, White Hispanic, or not
reported.

b

Brain MRI criteria as defined within the Centers for
Disease Control and Prevention Diagnostic Criteria
(high signal in caudate or putamen or at least 2
cortical regions [temporal, parietal, occipital] either
on diffusion-weighted imaging or fluid-attenuated
inversion recovery).5

c

Data were available from 21 patients undergoing a
procedure and for 88 patients without a history of a
procedure.

Sex
.28

Race

Medical history

Symptoms and signs at presentation

Results of investigations, No. of patients/total
No. (%)
Brain MRI consistent with CJDb
Time from symptom onset to first MRI,
median (range), mo
Abnormal EEG
Time from symptom onset to first EEG,
median (range), mo
CSF 14-3-3 positive

73/111 (66)

17/23 (74)

57/88 (65)

.41

Real-Time Quaking-Induced Conversion
positive

87/95 (92)

20/21 (95)

66/73 (90)

.48

CSF total tau protein >1150 pg/mL

88/92 (96)

20/21 (95)

68/72 (94)

.89

3.7 (0.4-37.4)

3.5 (0.4-37.4)

3.7 (0.4-23.4)

.34

109 (90)

21 (81)

88 (93)

.14

5.6 (0.9-56.9)

9.3 (1.4-56.9)

5.5 (0.9-37.4)

.37

Time from symptom onset to first CSF,
median (range), mo
Outcome data
Deceased
c

Symptomatic duration, median (range), mo
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providing data needed to replicate our findings and quantify the scope of the potential problem
posed by surgical procedures in patients with CJD.
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